OncoMatch/Clinical Trials/NCT06413680
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Is NCT06413680 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including REGN10597 and Cemiplimab for melanoma.
Treatment: REGN10597 · Cemiplimab — This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study drug(s) are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Melanoma
Renal Cell Carcinoma
Tumor Agnostic
Prior therapy
Must have received: standard-of-care therapy
confirmed progression on standard-of-care therapy
Cannot have received: Interleukin 2 (IL2), IL15, or IL-7 (outside adoptive cell therapy)
Exception: concurrent administration with adoptive cell therapy
Prior treatment with Interleukin 2 (IL2)/IL15/IL-7 given outside the context of concurrent administration with adoptive cell therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- University of California San Francisco (UCSF) · San Francisco, California
- Yale School of Medicine · North Haven, Connecticut
- University of Chicago · Chicago, Illinois
- Start Midwest Cancer Research · Grand Rapids, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06413680 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Interleukin 2 (IL2), IL15, or IL-7 (outside adoptive cell therapy) disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages